Recursion Pharmaceuticals (NASDAQ: RXRX), a small-cap biotech company, has one claim to fame: It currently owns the largest ...

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the company's lead drug. Read more here.

Here is the AI research roadmap for 2026: how agents that learn, self-correct, and simulate the real world will redefine ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer—has long captured the public imagination. Yet most arguments about it rest ...

I played these 25 cards the most and built so many decks around them — or at least dreamed how they might function in the ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...

Shanda Group has entered a period of renewed visibility, with a series of incubated ventures coming to light over the past several months. At the center of this momentum is its founder, Tianqiao Chen, ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

The surge of AI has, for an array of users, complicated tasks such as fixing a blocked bank account, reporting fraud or ...

The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...

Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...